Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment [Member]
Series B Preferred Stock [Member]
Series C Preferred Stock [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Series C Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Series B Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series C Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series D Preferred Stock [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Treasury Stock [Member]
Deferred Compensation [Member]
Balance at at Oct. 31, 2017 $ 101,256         $ 1   $ 1,045,203       $ (943,533)   $ (415) $ (280) $ 280
Balance at (in shares) at Oct. 31, 2017           5,791,068                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Sale of common stock, net of fees 7,129             7,129                
Sale of common stock, net of fees (in shares)           476,265                    
Exercise of warrants 3,326             3,326                
Exercise of warrants, (in shares)           216,309                    
Common stock issued, non-employee compensation 282             282                
Common stock issued, non-employee compensation, (in shares)           13,226                    
Share based compensation 3,238             3,238                
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans 660             660                
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans, (in shares)           (14,913)                    
Series C convertible preferred stock conversions       $ 20,220           $ 20,220            
Series C convertible preferred stock conversions, (in shares)             1,496,368                  
Preferred dividends — Series B (3,200)   $ (3,200)         (3,200)                
Series D Preferred stock redemption accretion         $ (2,075)           $ (2,075)          
Balance at at Oct. 31, 2018 82,194         $ 1   1,073,463       (990,867)   (403) (363) 363
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Effect of foreign currency translation 12                         12    
Adjustment for deferred compensation                               83
Adjustment for deferred compensation (in shares)           (5,637)                    
Adjustment for deferred compensation                             (83)  
Net loss (47,334)                     (47,334)        
Balance at (in shares) at Oct. 31, 2018           7,972,686                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Sale of common stock, net of fees 43,666         $ 12   43,654                
Sale of common stock, net of fees (in shares)           119,128,677                    
Common stock issued, non-employee compensation 102             102                
Common stock issued, non-employee compensation, (in shares)           29,454                    
Share based compensation 2,804             2,804                
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans 200             200                
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans, (in shares)           52,607                    
Series A warrant exchange, (in shares)           500,000                    
Series C convertible preferred stock conversions 15,489             15,489                
Series C convertible preferred stock conversions, (in shares)       3,914,218   3,914,218                    
Series C convertible preferred stock adjustment for beneficial conversion feature 6,586             6,586                
Series C convertible stock redemption value adjustments (14,597)             (14,597)                
Preferred dividends — Series B     (3,231)           $ (3,231)              
Series D convertible preferred stock conversions 31,183         $ 6   31,177                
Series D convertible preferred stock conversions, (in shares)           62,040,496                    
Series D Preferred stock redemption accretion         $ (3,793)           $ (3,793)          
Balance at at Oct. 31, 2019 75,737 $ (6,654)       $ 19   1,151,454       (1,075,089) $ (6,654) (647) (466) 466
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Effect of foreign currency translation (244)                         (244)    
Adjustment for deferred compensation                               103
Adjustment for deferred compensation (in shares)           (29,454)                    
Adjustment for deferred compensation                             (103)  
Net loss $ (77,568)                     (77,568)        
Balance at (in shares) at Oct. 31, 2019 193,608,684         193,608,684                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Sale of common stock, net of fees $ 171,911         $ 9   171,902                
Sale of common stock, net of fees (in shares)           86,307,932                    
Exercise of warrants 37,060         $ 1   37,059                
Exercise of warrants, (in shares)           14,696,320                    
Common stock issued, non-employee compensation 104             104                
Common stock issued, non-employee compensation, (in shares)           58,303                    
Reclassification of value of share based compensation upon approval of authorized shares for grant 401             401                
Share based compensation 1,868             1,868                
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans 3             3                
Taxes paid upon vesting of restricted stock awards, net of stock issued under benefit plans, (in shares)           49,434                    
Preferred dividends — Series B     $ (3,331)           $ (3,331)              
Balance at at Oct. 31, 2020 194,548         $ 29   $ 1,359,454       (1,164,196)   (739) (432) 432
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Effect of foreign currency translation (92)                         $ (92)    
Adjustment for deferred compensation                               $ (34)
Adjustment for deferred compensation (in shares)           (13,915)                    
Adjustment for deferred compensation                             $ 34  
Net loss $ (89,107)                     $ (89,107)        
Balance at (in shares) at Oct. 31, 2020 294,706,758         294,706,758